ProKidney Corp.
Andrew Bruce has extensive experience in bioprocess research and development, currently working at ProKidney Corp. since February 2023. Previously, Andrew served as Senior Director of Scientific Operations at Zen-Bio, Inc. and held various senior leadership roles in process and product development at OrganaBio, LLC and United Therapeutics Corporation, where responsibilities included overseeing the regenerative medicine lab. Andrew began a career in biotechnology as a Scientist at Tengion and Vesta Therapeutics, focusing on regenerative medicine technologies and cell therapies, and previously worked as a Senior Research Associate at Incara Pharmaceuticals, contributing to liver cell therapy development. Educational background includes a Bachelor of Science in Zoology from North Carolina State University.
This person is not in any offices
ProKidney Corp.
ProKidney (Nasdaq: PROK), a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases potentially drive meaningful improvement in kidney function. Late-stage CKD, Stage 3b - 4, is a key target for REACT™ therapy. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022. For more information, visit www.prokidney.com.